

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

M#

Client Ref.

037003-0275716

RECEIVED  
MAY 27 2003  
TECH CENTER  
1995-300-1600/2900

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: Anderson, et al.

Appln. No.: 09/383,916

Filing Date: August 26, 1999

Examiner: Gambel, P.

Group Art Unit: 1644

Date: May 20, 2003

Page 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
PG	AR 4,816,397	03/1989	Boss, et al.	435	68	
	BR 4,816,567	03/1989	Cabilly, et al.	530	387	
	CR 5,116,964	05/1992	Capon, et al.	536	27	
	DR					

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
	ER	0 171 496 B1	05/1993	EP	Taniguchi, et al.				
	FR	0 173 494 A2	03/1986	EP	Morrison, et al.				
	GR	0 239 400 B1	08/1994	EP	Winter, et al.				
	HR	0 194 276 A1	03/1986	EP	Neuberger, et al.				
	IR	0 555 880 A2, A3	08/1993	EP	Aruffo, et al.				
	JR	2 177 096 A	03/1986	GB	Neuberger, et al.				
	KR	WO 92/06193	04/1992	WO	Gorman, et al.				
	LR	WO 93/09812	05/1993	WO	Lederman, et al.				
	MR	WO 94/28912	12/1994	WO	Thompson, et al.				
	NR	WO 95/06481	03/1995	WO	Noelle, et al.				
	OR	WO 95/06666	03/1995	WO	Noelle, et al.				

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

PR	Armitage, R.J., et al., Molecular and biological characterization of a murine Nature, 357:80-82 (1992)			
QR	Ben-Nun, A. et al., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur J. Immunol. 11, 195-199 (1981)			
RR	Capon, D.J., et al. Designing CD4 immunoadhesins for AIDS therapy, Nature 337, 525-531 (1989)			
SR	Dautigny, A., et al., Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid, FEBS Lett. 188(1):33-36 (1985)			
TR	Durie, F.H., et al., The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease, Research in Immunology, 145(3), 200-205 & 244-249 (1994)			
UR	Durie, F.H., et al., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40, Science, 261:1328-1330 (1993)			
VR	Gerritse, K., et al., CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis, Proc. Natl. Acad. Sci. USA, 93:2499-2504 (1996)			
WR	Hafler, D.A., et al., The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis, Ann. NY Acad. Sci., 636:251-265 (1991)			

Pharmaceutical 8/6/03

PAT-1449 12/98



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/383,916		
		Filing Date	08/26/99		
		First Named Inventor	Anderson et al.		
		Art Unit	1644		
		Examiner Name	Gambel		
Sheet	1	of	1	Attorney Docket Number	37003-0275716(1995-30-0233D1)

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PG		US-6,162,432	12/19/00	Wallner et al.	
PG		US-5,885,579	3/23/99	Linsley et al.	
PG		US-5,747,034	05/05/98	de Boer et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED

APR 22 2003

TECH CENTER 1600/2300

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

Examiner Signature	Phump G. Smigel	Date Considered	8/8/03
--------------------	-----------------	-----------------	--------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	09/383,916
Filing Date	08/26/99
First Named Inventor	Anderson et al.
Group Art Unit	1644
Examiner Name	Gambel
Attorney Docket Number	37003-0275716(1995-30-0233D1)

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
pk		Blazar, B. et al., "Infusion of Anti-B7.1 (CD80) and Anti-By.2 (CD86) Monoclonal Antibodies Inhibits Murine..." Journal of Immunology 1996 157:3250-3259 ✓	
		Daikh et al., "The CD28-B6 Costimulatory Pathway and its role in Autoimmune Disease, Journ. of Leukocyte Biology, Vo. 62, August 1997pp. 156-162 ✓	
		Kahan et al, "Immunosuppressive Therapy", Current Opinion in Immunology (1992) 4:553-560 ✓	
		Nickoloff, B. et al., "T Lymphocytes in Skin Lesions of Psoriasis and Mycosis Fungoides..." Blood, Vol. 83, No. 9 (May 1994); pp. 2580-2586 ✓	
		Perrin et al., "Opposing effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on ..." Journ. of Neuroimmunology 65(1996) pp. 31-39 ✓	
		Yi-qun et al., "Differential Requirements for co-stimulatory signals from B7 family members..." Intl. Immunology, Vol. 8, No. 1, pp. 37-44 ✓	

Examiner Signature

pkw upc n max 8/8/03

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APR 02 2003

RECEIVED